Friday, June 26, 2020

Liraglutide as a Treatment for Overweight Individuals with and without Diabetes

Liraglutide was approved for type 2 diabetes treatment in 2010. And In 2014, liraglutide was approved for weight loss. Since most people with type 2 diabetes are also overweight or obese, it would seem that liraglutide would be a good candidate medication for treating those overweight or obese persons who don't have type 2 diabetes, and those overweight or obese persons who do have type 2 diabetes. One study has shown the efficacy of treating non-diabetic patients who are obese with liraglutide. And another study has shown the efficacy of treating type 2 diabetes patients who are overweight or obese with liraglutide.

To determine if liraglutide is a good medication for weight loss for persons who are obese, the investigators performed a meta-analysis to determine the efficacy and the safety of the drug for obese patients. In the analysis, five publications from such databases as EMBASE and Medline were studied. The investigators analyzed 4754 non-diabetic  obese patients by comparing the weight loss in a liraglutide group (2,996 participants) with the weight loss in a placebo group (1,758 particip0ants). The liraglutide group lost 5% more weight than the placebo group.

Therefore, the investigators concluded that "liraglutide [is] an effective and safe treatment for weight loss in...  obese, non-diabetic  individuals.”

Many individuals with type 2 diabetes are overweight. And some medications for treating diabetes, including insulin, can cause weight gain. So a study was done to determine if liraglutide can enable a patient to lose weight and also treat type 2 diabetes. The primary objective of the study was to determine if liraglutide (3.0 mg dose) was more effective in treating obese patients with type 2 diabetes than a placebo group.

The study was a randomized controlled study where the liraglutide 3.0 mg group consisted of 198 participants. The placebo group also consisted of 198 participants. All participants in the liraglutide group were subjected to intensive behavioral therapy (IBT).  And all study participants were being treated with basal insulin.

After 56 weeks, the investigators concluded that the liraglutide 3.0 mg group achieved a 5.8% average weight loss compared to 1.5% for the placebo group. The liraglutide 3.0 mg group also had “significantly greater reductions in mean HbA1c, mean daytime glucose values, and less need for insulin versus placebo…”

Based on the two studies above, it can be concluded that liraglutide is an effective medication for obese patients who are either diabetic or non-diabetic.


Post a Comment

Subscribe to Post Comments [Atom]

<< Home

Subscribe to Overfat Strategy Blog by Email